Business Context and Reporting Period
Company: Geron Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1998
Business Overview: Geron is a biopharmaceutical company focused on discovering and developing therapeutic and diagnostic products based on human embryonic stem cells and telomeres/telomerase. The company is in an early stage of development with no marketed therapeutic products. Revenue is primarily derived from collaborative research agreements with partners such as Pharmacia & Upjohn and Kyowa Hakko.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 1998 | Nine Months Ended Sep 30, 1998 | Balance Sheet (Sep 30, 1998) |
|---|---|---|---|
| Total Revenues | $1,528 | $5,288 | -- |
| Net Loss | $(2,761) | $(7,053) | -- |
| Net Loss Per Share (Basic/Diluted) | $(0.25) | $(0.63) | -- |
| Cash and Cash Equivalents | -- | -- | $6,204 |
| Total Investments (Short & Long Term) | -- | -- | $28,171 |
| Total Current Assets | -- | -- | $23,083 |
| Total Current Liabilities | -- | -- | $2,954 |
| Accumulated Deficit | -- | -- | $(53,120) |
Liquidity: As of September 30, 1998, the company held $34.4 million in cash, cash equivalents, and investments. Management estimates these resources, combined with contract payments and interest income, are sufficient to fund operations through 1999.
Material Changes vs. Prior Period
- Revenue: Total revenues for the three months ended September 30, 1998, decreased to $1.5 million from $2.2 million in the same period in 1997. This decline is attributed to reduced research funding under the Kyowa Hakko agreement effective April 1998. For the nine-month period, revenues increased to $5.3 million from $4.5 million, driven by the timing of revenue recognition from the Pharmacia & Upjohn agreement.
- Operating Expenses: Research and development expenses remained relatively stable at $3.8 million for the quarter and $11.3 million for the nine months compared to the prior year. General and administrative expenses increased to $994,000 for the quarter (from $818,000) and $2.8 million for the nine months (from $2.4 million), primarily due to higher legal and filing costs.
- Net Loss: The net loss for the three months increased to $2.8 million from $2.0 million due to reduced funding. However, the net loss for the nine months decreased to $7.1 million from $8.2 million, largely due to higher revenue recognition from collaborative agreements.
- Capital Structure: The company raised $19.3 million through the issuance of common and preferred stock during the nine-month period, significantly increasing cash reserves compared to the prior year.
Guidance, Outlook, and Risks
Outlook: Management expects net losses to increase in the future due to decreased funding from Kyowa Hakko. The company does not expect to receive significant revenues from therapeutic products for several years. It anticipates needing substantial additional capital to fund future operations beyond 1999.
Recent Developments: On November 5, 1998, Geron announced the successful derivation of human embryonic stem cells in collaboration with the University of Wisconsin-Madison and human pluripotent stem cells from cultured primordial germ cells with Johns Hopkins University.
Key Risks and Contingencies:
- Technological Uncertainty: No assurance that research will lead to marketable products; significant preclinical and clinical testing is required.
- Dependence on Collaborators: The company relies heavily on partners (Pharmacia & Upjohn, Kyowa Hakko, Boehringer Mannheim) for funding, clinical trials, and commercialization.
- Patent Protection: Uncertainty regarding the ability to obtain and enforce patents; potential infringement claims exist regarding the Embryonic Stem Cell program.
- Regulatory Approval: Products must undergo extensive FDA review; approval is not guaranteed.
- Year 2000 Compliance: Estimated project cost is $200,000 to ensure computer systems function correctly in the year 2000.
Investor Verification Checklist
- Verify the status and funding levels of the collaborative agreements with Pharmacia & Upjohn and Kyowa Hakko, specifically the impact of the reduced Kyowa Hakko funding.
- Confirm the timeline and capital requirements for the transition from research to preclinical and clinical trials for telomerase inhibitors.
- Assess the potential dilution impact from the conversion of Series A Convertible Preferred Stock (15,000 shares outstanding as of Sep 30, 1998).
- Review the progress of the human embryonic stem cell program and any associated ethical or regulatory hurdles.
- Monitor the company's cash burn rate against the $34.4 million liquidity position to validate the "through 1999" runway estimate.